Observing complications and responses in cancer patients treated with anti-VEGF therapies
A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
This study looks at how cancer patients treated with anti-VEGF therapies respond to the treatment and what complications they might face.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 170 (estimated) |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05108519 on ClinicalTrials.gov |
What this trial studies
This observational study collects data on complications and clinical responses in cancer patients undergoing treatment with anti-VEGF-related therapies at Emory University and the University of Texas M.D. Anderson Cancer Center. The primary objective is to explore the incidence of clinical complications associated with these therapies. Secondary objectives include examining the correlation between clinical response rates and a novel blood pressure scoring system, as well as the relationship between toxicity grades and treatment responses. Patient medical records will be reviewed to gather relevant information.
Who should consider this trial
Good fit: Ideal candidates are cancer patients currently receiving anti-VEGF-related therapies, either alone or in combination.
Not a fit: Patients not receiving anti-VEGF therapies or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the side effects of anti-VEGF therapies and improve treatment strategies for cancer patients.
How similar studies have performed: Other studies have explored the effects of anti-VEGF therapies, but this specific observational approach focusing on complications and a novel scoring system is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be able to understand and be willing to sign a written informed consent document * Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Nicolas L Palaskas — M.D. Anderson Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.